HIV Diagnostics Market, by Product Type (Instruments and Reagents & Kits), by Test Type (Screening, Differentiation & Confirmation Test, and Monitoring Test), by End User (Hospital and Clinics, Diagnostic Laboratories, Home Care Settings, and Others), and

HIV Diagnostics Market, by Product Type (Instruments and Reagents & Kits), by Test Type (Screening, Differentiation & Confirmation Test, and Monitoring Test), by End User (Hospital and Clinics, Diagnostic Laboratories, Home Care Settings, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Acquired Immunodeficiency Syndrome (AIDS) is caused by human immunodeficiency virus (HIV). HIV diagnosis tests are carried out to detect the presence of the virus. HIV diagnosis can be performed by blood test, saliva test, viral load test, though the most efficient test results are achieved by Enzyme Linked Immunosorbent Assay (ELISA) test initially and Western Bloat Method. ELISA test, which is enzyme linked immunosorbent assay, uses the antibodies to identify the substance and the western blot technique is used to detect anti –HIV antibodies in the human serum sample.
Market Dynamics
Increasing prevalence of HIV are expected to propel global demand for HIV diagnostics over the forecast period. For instance, according to the UNAIDS 2019 report, number of HIV cases increased from 37.2 million to around 37.9 million globally, from the year 2017 and 2021 respectively. Moreover, according to the UNAIDS 2019 report, around 1.7 million new cases of people globally living with HIV was reported in 2021.
Increasing collaborations and acquisitions by the market players are expected to drive the market growth over the forecast period. For instance, in 2016, Abbott Laboratories acquired Alere Inc, a manufacturer of rapid point-of-care diagnostic tests. The acquisition was done to add tests products for infectious diseases such as HIV, tuberculosis, malaria, influenza to Abbott Laboratories’ suite of products for testing genetic mutations and to boost diagnostics offerings of the company.
Moreover, rising product launches by the market players is expected to propel the market growth over the forecast period. For instance, in 2014, BD Biosciences, a segment of BD (Becton, Dickinson and Company) launched BD FACSPresto near patient CD4 counter system for HIV/AIDS patients, which provide lymphocytes and hemoglobin (Hb) concentration in blood samples to stage and monitor HIV/AIDS patients. Moreover, in July 2017, bioLytical Laboratories launched INSTI HIV Self-Test in pharmacies across the Netherlands, thereby providing access to HIV tests for early diagnosis. The INSTI product line is 99% accurate and provides test results in 60 seconds or less. Moreover, the company also offers contract services to adapt the INSTI platform to meet custom functional and technical diagnostic testing requirements.
Key features of the study:
This report provides in-depth analysis of the HIV diagnostics market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global HIV diagnostics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as part of this study include Abbott Laboratories, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol –Myres Squibb, Janssen Therapeutic, QIAGEN N.V., and ViiV Healthcare Ltd
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, technology upgradation, market expansion, and marketing tactics
The global HIV diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the HIV diagnostics market
Detailed Segmentation:
Global HIV Diagnostics Market, By Product Type:
Instruments
Reagents & Kits
Global HIV Diagnostics Market, By Test Type:
Screening
Third Generation (Antibody Test)
Laboratory-based
Point-of-Care
Fourth Generation (Antibody-Antigen (Ab/Ag) Test)
Laboratory-based
Point-of-Care
Others
Differentiation & Confirmation Test
Monitoring Test
CD4 Tests
Viral Load Tests
Global HIV Diagnostics Market, By End User:
Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others
Global HIV Diagnostics Market, By Region:
North America
By Product Type:
Instruments
Reagents & Kits
By Test Type:
Screening
Third Generation (Antibody Test)
Laboratory-based
Point-of-Care
Fourth Generation (Antibody-Antigen (Ab/Ag) Test)
Laboratory-based
Point-of-Care
Others
Differentiation & Confirmation Test
Monitoring Test
CD4 Tests
Viral Load Tests
By End User:
Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others
By Country:
U.S.
Canada
Latin America
By Product Type:
Instruments
Reagents & Kits
By Test Type:
Screening
Third Generation (Antibody Test)
Laboratory-based
Point-of-Care
Fourth Generation (Antibody-Antigen (Ab/Ag) Test)
Laboratory-based
Point-of-Care
Others
Differentiation & Confirmation Test
Monitoring Test
CD4 Tests
Viral Load Tests
By End User:
Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Instruments
Reagents & Kits
By Test Type:
Screening
Third Generation (Antibody Test)
Laboratory-based
Point-of-Care
Fourth Generation (Antibody-Antigen (Ab/Ag) Test)
Laboratory-based
Point-of-Care
Others
Differentiation & Confirmation Test
Monitoring Test
CD4 Tests
Viral Load Tests
By End User:
Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type:
Instruments
Reagents & Kits
By Test Type:
Screening
Third Generation (Antibody Test)
Laboratory-based
Point-of-Care
Fourth Generation (Antibody-Antigen (Ab/Ag) Test)
Laboratory-based
Point-of-Care
Others
Differentiation & Confirmation Test
Monitoring Test
CD4 Tests
Viral Load Tests
By End User:
Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type:
Instruments
Reagents & Kits
By Test Type:
Screening
Third Generation (Antibody Test)
Laboratory-based
Point-of-Care
Fourth Generation (Antibody-Antigen (Ab/Ag) Test)
Laboratory-based
Point-of-Care
Others
Differentiation & Confirmation Test
Monitoring Test
CD4 Tests
Viral Load Tests
By End User:
Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type:
Instruments
Reagents & Kits
By Test Type:
Screening
Third Generation (Antibody Test)
Laboratory-based
Point-of-Care
Fourth Generation (Antibody-Antigen (Ab/Ag) Test)
Laboratory-based
Point-of-Care
Others
Differentiation & Confirmation Test
Monitoring Test
CD4 Tests
Viral Load Tests
By End User:
Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Abbott Laboratories*
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
Bio-Rad Laboratories, Inc.
Hologic, Inc.
Siemens Healthineers
Roche AG
Beckman Coulter Inc.
OraSure Technologies, Inc.
Becton, Dickinson and Company
Merck KGaA
Chembio Diagnostic Systems, Inc.
Zyomyx Incorporation
Bristol –Myres Squibb
Janssen Therapeutic
QIAGEN N.V.
ViiV Healthcare Ltd
“*” marked represents similar segmentation in other categories in the respective section.